Compositions and methods for treating neurodegenerative conditions
OwnerJaime Grutzendler, Peng Yuan +2inventors
InventorsJaime Grutzendler, Peng Yuan, Mengyang Zhang, Lei Tong
Life of this patent
Estimating the term…
Abstract
Described herein is a method of treating, ameliorating and/or preventing a neurodegenerative disease in a subject. The method includes administer to the subject a compound that reverses, ameliorates, and/or prevents a formation or enlargement of an axonal spheroid in a neuron of the subject. Also described herein is a method of reversing, ameliorating, and/or preventing a formation or enlargement of an axonal spheroid, as well as a compound for treating, ameliorating and/or preventing a neurodegenerative disease in a subject.
Claims20
A method of treating, or ameliorating a neurodegenerative condition in a subject in need thereof, the method comprising
- administering to the subject a compound that reverses, ameliorates, or prevents formation or enlargement of an axonal spheroid in a neuron of the subject.
A method of reversing, ameliorating, or preventing a formation or enlargement of an axonal spheroid, the method comprising:
- contacting a neuron affected by the formation or enlargement of the axonal spheroid with a compound that:
- downregulates an activity or expression level of phospholipase D3 (PLD3) in a neuron;
- upregulates an activity or expression level of transcription factor EB (TFEB) in a neuron;
- or
- upregulates an activity or expression level of autophagy-related protein 5 (ATG5) in a neuron.
A pharmaceutical composition for treating a neurodegenerative condition in a subject, the pharmaceutical composition comprising:
- a compound that:
- downregulates an activity or expression level of phospholipase D3 (PLD3) in a neuron affected by the neurodegenerative condition;
- upregulates an activity or expression level of transcription factor EB (TFEB) in a neuron affected by the neurodegenerative condition;
- or
- upregulates an activity or expression level of autophagy-related protein 5 (ATG5) in a neuron affected by the neurodegenerative condition;
- and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.